Skip to content

High-flow nasal cannula versus conventional oxygen therapy in high-risk patients during bronchoscopy: a randomized controlled trial protocol

High-flow nasal cannula versus conventional oxygen therapy in high-risk patients during bronchoscopy: a randomized controlled trial protocol

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100055038
Enrollment
Unknown
Registered
2021-12-31
Start date
2022-09-30
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory diseases

Interventions

High flow oxygen group:OH-70C (micomme, HuNan, China) will be used to provide HFNC, with flow of 50 L/min and FIO2 at 0.45. The temperature will be set at 37 degree C..
Conventional oxygen therapy group:During the bronchoscopy, the nasal cannula was used for oxygen therapy, and the oxygen inhalation flow was set to 6L/min

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Hypoxemia with PaO2/FIO2=45 mmHg, baseline chronic lung disease, including COPD, bronchiectasis, etc.; 3. Tracheal stenosis confirmed by radiology before bronchoscopy may be caused by tracheomalacia, tracheal tumor or granuloma, or inhalation of foreign bodies; 4. Morbidly obese patients with body mass index (BMI) >= 30kg/m^2.

Exclusion criteria

Exclusion criteria: 1.Refuse to participate; 2.Local/general anesthesia bronchoscopy or rigid endoscopy is indicated; 3.Aged >= 90 years; 4.Pregnancy; 5.Estimated duration of bronchoscopy is less than 10 minutes; 6.Contraindication to using HFNC, including nasopharyngeal obstruction and blockage; 7.Require oxygen flow = 3L/min to maintain SpO2 at 90-97%; 8.Central airway narrowness >80%; 9.The patient is critically ill and unsuitable for study inclusion assessed by anesthesiologists and pulmonologists.

Design outcomes

Primary

MeasureTime frame
the incidence of desaturation which is defined as SpO2 < 90% between patients using HFNC and those using COT;

Secondary

MeasureTime frame
the timing of the appearance of the first desaturation;lowest SpO2;highest transcutaneous partial pressure of carbon dioxide;the need for treatment escalation and airway management; the number and duration of bronchoscopy suspensions;the recovery time between the two groups;the incidence of adverse events;

Countries

China

Contacts

Public ContactZhang Wei

Shanghai Changhai Hospital

zhangweismmu@126.com+86 138 1780 4080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026